|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NDST1 |
Gene summary for NDST1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NDST1 | Gene ID | 3340 |
| Gene name | N-deacetylase and N-sulfotransferase 1 | |
| Gene Alias | HSST | |
| Cytomap | 5q33.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | B7Z1Q0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3340 | NDST1 | LZE24T | Human | Esophagus | ESCC | 3.85e-02 | 8.68e-02 | 0.0596 |
| 3340 | NDST1 | P2T-E | Human | Esophagus | ESCC | 9.72e-07 | 1.14e-01 | 0.1177 |
| 3340 | NDST1 | P5T-E | Human | Esophagus | ESCC | 5.50e-08 | 9.51e-02 | 0.1327 |
| 3340 | NDST1 | P8T-E | Human | Esophagus | ESCC | 2.17e-07 | 7.37e-02 | 0.0889 |
| 3340 | NDST1 | P9T-E | Human | Esophagus | ESCC | 8.59e-06 | 1.28e-01 | 0.1131 |
| 3340 | NDST1 | P10T-E | Human | Esophagus | ESCC | 5.99e-03 | 8.35e-02 | 0.116 |
| 3340 | NDST1 | P11T-E | Human | Esophagus | ESCC | 1.37e-07 | 3.34e-01 | 0.1426 |
| 3340 | NDST1 | P12T-E | Human | Esophagus | ESCC | 6.62e-06 | 1.46e-01 | 0.1122 |
| 3340 | NDST1 | P15T-E | Human | Esophagus | ESCC | 2.50e-03 | 1.22e-01 | 0.1149 |
| 3340 | NDST1 | P16T-E | Human | Esophagus | ESCC | 9.22e-12 | 1.06e-01 | 0.1153 |
| 3340 | NDST1 | P17T-E | Human | Esophagus | ESCC | 4.06e-04 | 1.49e-01 | 0.1278 |
| 3340 | NDST1 | P19T-E | Human | Esophagus | ESCC | 3.58e-05 | 3.34e-01 | 0.1662 |
| 3340 | NDST1 | P21T-E | Human | Esophagus | ESCC | 6.69e-13 | 1.70e-01 | 0.1617 |
| 3340 | NDST1 | P22T-E | Human | Esophagus | ESCC | 1.91e-09 | 9.90e-02 | 0.1236 |
| 3340 | NDST1 | P23T-E | Human | Esophagus | ESCC | 1.25e-04 | 9.99e-02 | 0.108 |
| 3340 | NDST1 | P24T-E | Human | Esophagus | ESCC | 4.13e-06 | 8.47e-02 | 0.1287 |
| 3340 | NDST1 | P26T-E | Human | Esophagus | ESCC | 1.40e-05 | 7.42e-02 | 0.1276 |
| 3340 | NDST1 | P27T-E | Human | Esophagus | ESCC | 3.35e-11 | 1.26e-01 | 0.1055 |
| 3340 | NDST1 | P28T-E | Human | Esophagus | ESCC | 2.41e-09 | 1.79e-01 | 0.1149 |
| 3340 | NDST1 | P30T-E | Human | Esophagus | ESCC | 1.76e-07 | 2.65e-01 | 0.137 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:00442725 | Esophagus | ESCC | sulfur compound biosynthetic process | 96/8552 | 148/18723 | 1.86e-06 | 2.16e-05 | 96 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00442626 | Esophagus | ESCC | cellular carbohydrate metabolic process | 160/8552 | 283/18723 | 1.43e-04 | 9.66e-04 | 160 |
| GO:003090118 | Esophagus | ESCC | midbrain development | 58/8552 | 90/18723 | 2.52e-04 | 1.55e-03 | 58 |
| GO:00160514 | Esophagus | ESCC | carbohydrate biosynthetic process | 117/8552 | 202/18723 | 2.96e-04 | 1.79e-03 | 117 |
| GO:00485687 | Esophagus | ESCC | embryonic organ development | 228/8552 | 427/18723 | 7.28e-04 | 3.79e-03 | 228 |
| GO:00487052 | Esophagus | ESCC | skeletal system morphogenesis | 120/8552 | 220/18723 | 4.90e-03 | 1.89e-02 | 120 |
| GO:0006029 | Esophagus | ESCC | proteoglycan metabolic process | 48/8552 | 79/18723 | 4.93e-03 | 1.89e-02 | 48 |
| GO:0030166 | Esophagus | ESCC | proteoglycan biosynthetic process | 35/8552 | 56/18723 | 8.30e-03 | 2.94e-02 | 35 |
| GO:0006024 | Esophagus | ESCC | glycosaminoglycan biosynthetic process | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
| GO:0006023 | Esophagus | ESCC | aminoglycan biosynthetic process | 47/8552 | 79/18723 | 9.29e-03 | 3.23e-02 | 47 |
| GO:19048881 | Esophagus | ESCC | cranial skeletal system development | 41/8552 | 68/18723 | 1.07e-02 | 3.66e-02 | 41 |
| GO:0030201 | Esophagus | ESCC | heparan sulfate proteoglycan metabolic process | 21/8552 | 31/18723 | 1.10e-02 | 3.70e-02 | 21 |
| GO:00346372 | Esophagus | ESCC | cellular carbohydrate biosynthetic process | 46/8552 | 78/18723 | 1.24e-02 | 4.13e-02 | 46 |
| GO:00442623 | Liver | NAFLD | cellular carbohydrate metabolic process | 55/1882 | 283/18723 | 1.27e-06 | 6.01e-05 | 55 |
| GO:0016051 | Liver | NAFLD | carbohydrate biosynthetic process | 43/1882 | 202/18723 | 1.55e-06 | 6.96e-05 | 43 |
| GO:00067904 | Liver | NAFLD | sulfur compound metabolic process | 58/1882 | 339/18723 | 3.79e-05 | 9.38e-04 | 58 |
| GO:0034637 | Liver | NAFLD | cellular carbohydrate biosynthetic process | 20/1882 | 78/18723 | 6.46e-05 | 1.39e-03 | 20 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NDST1 | SNV | Missense_Mutation | c.2011G>A | p.Asp671Asn | p.D671N | P52848 | protein_coding | tolerated(0.13) | probably_damaging(0.978) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| NDST1 | SNV | Missense_Mutation | novel | c.1531N>T | p.Gly511Trp | p.G511W | P52848 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| NDST1 | SNV | Missense_Mutation | c.2611N>T | p.Pro871Ser | p.P871S | P52848 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NDST1 | SNV | Missense_Mutation | novel | c.1382A>C | p.Tyr461Ser | p.Y461S | P52848 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| NDST1 | SNV | Missense_Mutation | c.2016N>G | p.Phe672Leu | p.F672L | P52848 | protein_coding | tolerated(0.24) | benign(0.108) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| NDST1 | SNV | Missense_Mutation | rs372636224 | c.2624G>T | p.Arg875Leu | p.R875L | P52848 | protein_coding | deleterious(0.01) | possibly_damaging(0.847) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| NDST1 | insertion | Frame_Shift_Ins | novel | c.2587_2588insAGTGCAATCGCGTGATCTTGGCTCACTGCAACCTCCGCTTTCCGGG | p.Leu863GlnfsTer18 | p.L863Qfs*18 | P52848 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| NDST1 | insertion | Nonsense_Mutation | novel | c.649_650insCAAATTAGAACCTGTCATCCTTTG | p.Lys217delinsThrAsnTerAsnLeuSerSerPheGlu | p.K217delinsTN*NLSSFE | P52848 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NDST1 | deletion | Frame_Shift_Del | c.205delN | p.Pro69HisfsTer110 | p.P69Hfs*110 | P52848 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| NDST1 | SNV | Missense_Mutation | rs182500942 | c.1411C>T | p.Arg471Cys | p.R471C | P52848 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |